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Background: Gastric cancer (GC) development is a multistep process, during which numerous alterations
accumulate in nuclear and mitochondrial DNA. A deficiency of repair machinery brings about an accumulation of errors
introduced within simple repetitive microsatellite sequences during replication of DNA. Aberrant methylation is related
to microsatellite instability (MSI) by the silencing of the hMLH1 gene. The aim of this study is to investigate a possible
relationship between the RUNX3 promoter methylation, nuclear microsatellite instability (nMSI) and mitochondrial
microsatellite instability (mtMSI), in order to clarify its biological role in GC.
Patients and methods: nMSI and mtMSI were evaluated in a consecutive series of 100 GC patients. For the
analysis of the nMSI, we followed the National Cancer Institute guidelines. mtMSI was assessed by analyzing a portion
of the displacement-loop region. The aberrant methylation of RUNX3 was analyzed in 40 GC patients by methylation-
specific PCR.
Results: Overall, 55% of GC demonstrated methylation of the RUNX3 promoter; 82% of GC was classified as stable
microsatellite instability, 5% as low-level microsatellite instability and 13% as high-level microsatellite instability (MSI-H);
mtMSI was detected in 11% of GC. A significant association was found between mtMSI and tumor–node–metastasis
staging, furthermore an interesting association between MSI-H status, mtMSI and RUNX3 methylation.
Conclusion: These data suggest that RUNX3 is an important target of methylation in the evolution of mtMSI and
nMSI-H GC.
Key words: gastric cancer, methylation-specific PCR (MSP), mitochondrial microsatellite instability (mtMSI), nuclear
microsatellite instability (nMSI), RUNX3
introduction
Gastric cancer (GC) is the second most common malignant
neoplasm throughout the world and the second most frequent
cause of cancer death [1]. GC development is a multistep
process, during which numerous genetic and epigenetic
alterations accumulate. In various human malignancies,
alterations do not only involve nuclear but also mitochondrial
DNA. Microsatellite instability (MSI) phenotype is
characterized by the presence of errors during DNA replication,
such as small deletions and or insertions, within simple
repetitive microsatellite sequences [2]. In order for the cell to
accurately copy its genome during cellular proliferation, the
DNA mismatch repair (MMR) complex is essential.
Deficiencies of this system result in a subsequent failure to
repair errors introduced during replication of DNA [3]. The
mitochondrial genome (mtDNA) is made up of 16 569 bp
and encodes 13 polypeptides, 22 transfer RNAs and two
ribosomal RNAs, all of which are essential for electron
transport and ATP generation. All the mitochondrial genes
are organized continuously, there being only two noncoding
regions. The 1.1-kb displacement (D)-loop contains the
main regulatory sequences for transcription and replication
initiation [4]. A mononucleotide repetition of poly-C, (D310),
has been identified among the nucleotides 16184 and 16193 and
can be considered as a marker for the study of mitochondrial
instability in GC [5]. For the analysis of the nuclear
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microsatellite instability (nMSI), we followed the guidelines
provided by the National Cancer Institute (NCI) in 1997
recommending a panel of five microsatellite markers [6].
Nuclear MSI can be classified as high-level microsatellite
instability (MSI-H), low-level microsatellite instability
(MSI-L) or stable microsatellite instability (MSS). No
correlation between nuclear and mitochondrial MSI was
found in colorectal, breast and renal cancers [7]. Results
involving GC, however, prove to be fairly controversial [8, 9,
32]. A further molecular defect described in gastric cancer is
aberrant methylation of the cytosine within the CpG islands,
a phenomenon associated with loss of gene expression by
transcription repression [10]. Some GCs show a high degree
of concordant methylation of CpG islands; these types of
tumors are classified as high CpG island methylator
phenotypes (CIMP) [9]. CIMP is closely related to MSI
phenotypes; in fact in most sporadic GCs, nMSI is due to
the silencing of hMLH1, which is a MMR gene [11–14]. In
addition to aberrant methylation of the 5# CpG islands of
hMLH1, several other tumor-related genes such as
E-cadherin, APC, RASSF1A, DCC and PTEN have also been
described in GC [15–19]. Recently, RUNX3 has been shown to
be among the gene promoters that are most specifically
methylated in CIMP-positive gastric cancer [20]. RUNX3 is
a tumor suppressor gene located on chromosome 1p36,
a region that is thought to carry a tumor suppressor gene
implicated in various types of cancers, especially those of the
gastrointestinal tract [21]. Together with RUNX1 and RUNX2,
it belongs to the runt related transcription factors (RUNXs),
which respond to the growth, differentiation and apoptosis
signals induced by the TGF-b pathway [22–24]. RUNX3 loss
of expression by promoter hypermethylation is involved in
roughly half of the cases of GC and is mostly cancer specific,
although recent studies have demonstrated that promoter
methylation occurs also in non-neoplastic cells during aging
[25, 26]. No study to date has examined relationship between
RUNX3 promoter methylation, nMSI and mitochondrial
microsatellite instability (mtMSI) in GC. The purpose of this
study was to investigate a possible relationship between these
events in order to clarify the biological role in GC and to
associate the resulting data with available clinicopathological
variables.
patients and methods
clinicopathological variables
A prospective study was conducted on a consecutive series of 100
patients affected by GC who had undergone potentially curative
surgical resection at the Department of Oncology of Palermo University
between 1999 and 2007. The following clinicopathological variables were
taken into account: sex, age, tumor site, tumor size, tumor histotype,
histological grade, tumor–node–metastasis (TNM) staging, invasion, and
lymph node status (Table 1). None of the patients had undergone radio
or chemotherapy before surgery; curative resection included gastrectomy
and wide dissection of the regional lymph nodes. The excised GC and
the lymph nodes were examined and staged according to the most
recent TNM classification. Histological sections of the 100 operated
pieces were examined separately by two pathologists (Rosa Maria Tomasino
and Vincenza Morello). Lauren’s criteria were used in order to classify the
tumors into intestinal or diffuse types. Differentiation was evaluated and
classified as G1, G2 or G3.
sampling
After obtaining informed consent, multiple samples (from 3 to 10) were
taken from the various representative areas of the primary GC within
30 min of surgical resection. Each tissue specimen was carefully analyzed
to make sure that, as far as possible, all non-neoplastic material had been
removed and also to eliminate nonvital areas. Furthermore, a sample of
apparently healthy mucosa as far away as possible from the tumor was
taken from each patient to be used as a standard control for the subsequent
biomolecular investigation. After sampling, all tissues were immediately
frozen and stored at 280C.
Table 1. Clinicopathological variables of the 100 GC patients
Clinicopathological variables Patients (%)
Sex
Male 65
Female 35
Age
<60 29
60–69 36
>70 35
Tumor site
Antrum 26
Corpus 30
Cardias or Fundus 29
Unknown 15
Tumor size (cm)
<5 31
>5 68
Unknown 1
Tumor histotype
Intestinal 55
Diffuse 24
Mixed 3
Unknown 18
Histological grade
Well differentiated (G1) 7
Moderately differentiated (G2) 40
Poorly differentiated (G3) 51
Unknown 2
TNM staging
I 27
II 34
III 29
IV 8
Unknown 2
Invasion
PS– 37
PS+ 25
Unknown 38
Lymph node status
Negative 39
Positive 58
Unknown 3
GC, gastric carcinoma; TNM, tumor–node–metastasis.
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tissue DNA extraction
DNA was extracted both from the tumoral gastric tissue and from the
mucosa by means of a mini QIAamp DNA kit (Qiagen, Hilden, Germany),
according to the manufacturers instructions.
nMSI and mtMSI
For the analysis of the nMSI, we followed the NCI guidelines, which in 1997
recommended a panel of five microsatellite markers for detection of MSI,
consisting of two mononucleotide-repeats (BAT-25 and BAT-26) and three
dinucleotide repeats (D2S123, D5S345 and D17S250). This panel of
markers is referred to as the Bethesda panel [6] and provides a uniform set
of markers and criteria for tumor classification that has helped standardize
MSI analysis. PCR was performed on a total volume of 15 ll with the use of
30 ng of genomic DNA, 1.5 ll of 10· 25 mM MgCl2 buffer, 0.6 ll of
25 mM MgCl2, 0.6 ll of 10 mM deoxyribonucleotide triphosphate (dNTP),
0.12 ll of 5 U/ll AmpliTaq Gold (Applied Biosystems, Foster City, CA),
1 ll of 5 lM FAM or HEX-labeled forward primer and 1 ll of 5 lM
unlabeled reverse primer.
Mitochondrial instability was assessed by analyzing a portion of the
D-loop, the mononucleotide tract of poly-C (D310) made up of 12–18 C
interrupted by a T at bp10, following the same conditions for the PCR
of nMSI but with the use of specific primers for the D310 region: FAM-
labeled forward primer 5#-ACA GCC ACT TTC CAC ACA G-3# and
reverse primer 5#-TGG TTA GGC TGG TGT TAG GG-3#. Most of the
alterations generally occur in the upstream portion of T.
The reaction was assessed on the GeneAmp 9700 (Applied Biosystems).
Amplification was started with 12 min at 95C, followed by 10 cycles
composed of 15 s at 94C, 15 s at 55C and 30 s at 72C. This was
followed by 25 cycles composed of 15 s at 89C, 15 s at 55C and 30 s at
72C. Approximately 1–2 ng of each PCR product were mixed with a 1:40
dilution of formamide-Gene scan 400 HD standard size (Applied
Biosystems), denatured at 95C for 2 min and visualized on an ABI PRISM
3100 Avant Genetic Analyzer (Applied Biosystems) Applied Biosystems.
DNA alterations were detected using a GeneMapper software version 3.5.
Samples were considered positive for MSI when alternate-sized bands were
present in the tumor DNA but absent in mucosa DNA. Tumors showing
nuclear instability were classified as MSI-H when two or more markers
showed allelic shifts, as MSI-L if only one marker shows an allelic shift and
as MSS when no marker showed an allelic shift. Tumors showing mtMSI
were confirmed by direct sequencing on ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems). The results were analyzed with the use of the
software Sequencing Analysis 5.1 in order to detect the possible coexistence
of several different variants (mutated or wild type) along the mononucleot
tract (heteroplasmy).
Methylation Specific PCR
DNA methylation of RUNX3 was determined by methylation-specific PCR
(MSP). MSP distinguishes unmethylated (UM) from M alleles of a given
gene based on DNA sequence alterations after bisulfite treatment of DNA,
which converts UM but not M, cytosines to uracils. Subsequent PCR using
primers specific to sequences corresponding to either M or UM DNA
sequences is then performed. Bisulfite modification of genomic DNA was
carried out essentially as described previously [27]. Briefly, 2 lg of genomic
DNA was denatured with 5.5 ll of 2 M NaOH, freshly prepared for 10 min
at 37C. We then added and mixed 30 ll of freshly prepared 10 mM
hydroquinone and 520 ll of freshly prepared 3 M sodium bisulfite at pH 5.
The samples were then incubated in mineral oil for 16 h at 50C. The
modified DNA was purified with a Wizard DNA clean-up system
(Promega, Madison, WI). After purification, the samples were treated
with NaOH (0.3 M) for 5 min at 37C. The DNA was then ethanol
precipitated and resuspended in 20 ll of water for MSP analysis. The
bisulfite-induced changes affecting UM and M alleles were detected by PCR.
Primer sequences for the UM reaction were 5#-TTATGAGGGGTGGTTGT
ATGTGGG-3#(forward) and 5#-AAAACAACCAACACAAACACCTCC-3#
(reverse), and primer sequences for the M reaction were 5#-
TTACGAGGGGCGGTCGTACGCGGG-3# (forward) and 5#-
AAAACGACCGACGCGAACGCCTCC-3# (reverse). The primers, which
amplify the proximal regional (- 218 and - 69) of the initial transcription
site, were designed by taking into consideration the whole sequence of the
gene codifying RUNX3, containing also the P2 promoter sequence
(GeneBank Access number AL023096), where there is a long CpG (4.2 kb)
island. The PCR was performed in a total volume of 50 ll, using 5 ll of 10·
25 mMMgCl2 buffer, 1.5 ll of dNTP 10 mM, 2.5 ll of forward primer (UM
and M) 10 lM, 2.5 ll of reverse primer (UM and M) 10 lM, 0.3 ll of 5U/ll
AmpliTaq Gold (Applied Biosystems) and about 30 ng of bisulfite-modified
DNA. The amplification was performed on GeneAmp 9700 thermocycler
(Applied Biosystems) under the following conditions: predenaturation at
95C for 10 min, 35 amplification cycles (denature at 94C for 30 s,
annealing at 66C for 40 s and extension at 72C for 1 min) and final
extension at 72C for 7 min. The product indicative of an UM RUNX3
allele and of a M RUNX3 allele were analyzed on 2% agarose gels and
photographed. CpG Universal M DNA (Chemicon International, CA)
was used as the positive control for M alleles, CpG Universal UM DNA
(Chemicon International), as a negative control for M genes, 100 bp
DNA ladder as size marker. MSP assay for each sample was repeated at
least twice.
bisulfite sequencing
In order to verify MSP, bisulfite sequencing was performed by automated
sequencing using the Big Dye Terminator v3.1 Cycle Sequencing Kit and
the model ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
statistical analysis
Associations between biomolecular and clinicopathological variables were
evaluated by the chi-square test with Yates correction, where appropriate. A
P value <0.05 was considered statistically significant.
results
methylation status of RUNX3 in gastric cancers
To determine aberrant CpG island methylation of RUNX3,
we analyzed the promoter region spanning the transcription
start site of 40 gastric cancers using MSP. In total, 55%
(22/40) of GC demonstrated complete methylation of the
RUNX3 promoter. M GC always displayed evidence of an
accompanying UM PCR product (Figure 1). These UM
RUNX3 alleles most likely reflect either the unavoidable
presence of normal cells in the cancer specimen or
heterogeneity of the methylation event within the tumor cell
population itself. Methylation observed is relatively cancer
specific since only two of 40 cases showed evidence for
aberrant RUNX3 methylation in the normal mucosa of older
patients (data not shown). Bisulfite direct sequencing was
performed on all of these normal and tumor samples to
confirm the accuracy of the MSP results (Figure 2).
nuclear MSI
None of the 100 patients analyzed had a family history of
gastric cancer. Overall, 82% of GC was classified as MSS, 5%
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as MSI-L and 13% as MSI-H. The representative examples of
MSI-H and MSI-L GC are shown in Figure 3. Of the GCs
presenting MSI-H, 10 demonstrated instability in all five
microsatellite markers (Figure 3A), two in BAT 25, BAT 26,
D2S123 and D5S346 (Figure 3B) and one in BAT 25, BAT 26
and D2S123 (Figure 3C). It is interesting to note that instability
in D2S123 was detected in all the five tumors with MSI-L
(Figure 3D).
mitochondrial MSI
mtMSI was detected in 11% (11/100) of GC. Seven (64%) of
the changes were deletions and four (36%) were insertions.
Most of the deletions and insertions involved 1–2 bp. The
largest alteration was a 4-bp deletion seen in two cases. In one
case there was a 3 bp insertion. An example of the DNA
fragment and sequencing analysis is shown in Figure 4. After
analysis of chromatograms obtained by DNA sequencing, seven
of 11 (64%) of alterations were evaluated to be heteroplasmic
and four of 11 (36%) homoplasmic.
relationship between mtMSI, nMSI, RUNX3
methylation status and clinicopathological
variables
The clinicopathological variables of GC patients are
summarized in Table 1. No significant association was found
between biological variables analyzed and sex, age, tumor site,
tumor size, tumor histotype histological grade, invasion or
lymph node status (data not shown). The only significant
association was detected between mtMSI and TNM staging
(P < 0.025) (Table 2). Statistical analysis highlighted an
interesting association between MSI-H status, mtMSI and
RUNX3 methylation (Tables 2 and 3).
discussion
Tumor-related genes tend to be preferentially inactivated by
specific genetic or epigenetic mechanisms. Accumulating
evidence suggests that epigenetic silencing of tumor suppressor
genes due to aberrant hypermethylation of gene promoter
regions play an important role in gastric cancer
pathophysiology [28]. Concordant methylation of multiple
genes (termed CIMP) has been reported in carcinomas from
diverse sites. The methylation affects several critical molecular
pathways leading to cell immortalization and transformation,
including alterations in cell cycle regulation, metabolic
detoxification enzymes, cellular adherence and the DNA
damage response pathways [29]. Recently, a causal relationship
has been identified between aberrant methylation of the
promoter of RUNX3 and the incidence of gastric cancer in
humans [20]. The results obtained from this study
demonstrated that 55% (22/40) of human GCs presented
hypermethylation of the promoter region of the gene and
only two of 40 cases also showed methylation of the RUNX3
promoter in the nonmalignant gastric tissue. Our results
indicate that RUNX3 promoter methylation is a cancer-
specific event. A possible explanation for detecting
methylation in normal gastric tissues is that the methylation
of RUNX3 has been attributed to the aging process, and this
is similar to previous findings in which methylation was
observed in people >70 years of age [26]. The data reported
in literature show differences in methylation frequency of the
gene RUNX3. In a previous study, Waki et al. [26] reported
that RUNX3 methylation was observed in 45% of GCs; other
investigators reported that RUNX3 methylation was observed
in 71% of GCs [30]. These data can be explained by the fact
that different regions were examined within the RUNX3
CpG island. Homma et al. [31] studied the whole RUNX3
CpG island and showed that the 5# outskirt region is not
informative. In contrast, methylation spanning the
transcription start site within the RUNX3 promoter CpG
island is predominantly cancer specific and is critical for
gene silencing. In our study of sporadic GCs, the association
between RUNX3 promoter methylation, nMSI and mtMSI
showed significant associations, suggesting that these cancers
have acquired a methylator phenotype. The mechanism of
cancer development proposed for sporadic MSI-H GCs is the
aberrant promoter methylation of hMLH1 with the consequent
functional loss of MMR genes [14]. All the mtDNA repair
machinery is encoded by nDNA, and the corresponding gene
Figure 1. Representative examples of RUNX3 promoter methylation by
MSP in gastric cancer. Methylated (M), unmethylated (UM), negative
control (N), positive control (P), size marker (SM).
Figure 2. (A) Representative illustrations of RUNX3 CpG island. (B)
Electropherogram of unmethylated RUNX3 promoter. The underlined T
indicates that it was converted from C by bisulfite treatment, suggesting
that the residue was not methylated. (C) Sequence chromatogram of
methylated RUNX3 promoter. The underlined C indicates that it was
resistant to bisulfite treatment, suggesting that the residue was methylated.
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Figure 3. Representative allelic profiles of the five mononucleotide markers used for the determination of nMSI status. New alleles present in MSI-H and
MSI-L samples were indicated with an arrow.
Table 2. Association between RUNX3 methylation, nMSI and mtMSI in
gastric cancers
RUNX3 unmethylated,
fraction (%)
RUNX3 methylated,
fraction (%)
P value
Total: 40
nMSI
MSI-S 18/18 (100) 9/22 (41) £0.01
MSI-L 0/18 (0) 0/22 (0)
MSI-H 0/18 (0) 13/22 (59)
mtMSI
mtMSI 0/18 (0) 11/22 (50) £0.01
mtMSS 18/18 (100) 11/22 (50)
MSI, microsatellite instability; nMSI, nuclear MSI; mtMSI, mitochondrial
MSI; MSI-S, stable MSI; MSI-L, low-level MSI; MSI-H, high-level MSI;
mtMSS, mitochondrial stable MSI.
Table 3. Association between mtMSI, TNM staging and nMSI in gastric
cancers
mtMSS,
fraction (%)
mtMSI,
fraction (%)
P value
TNM staging
I 19/78 (24) 7/11 (64) £0.025
II 28/78 (36) 0/11 (0)
III 24/78 (31) 4/11 (36)
IV 7/78 (9) 0/11 (0)
nMSI
MSI-S 77/80 (96) 1/11 (9) £0.01
MSI-L 0/80 (0) 1/11 (9)
MSI-H 3/80 (4) 9/11(82)
MSI, microsatellite instability; mtMSI, mitochondrial MSI; TNM, tumor–
node–metastasis; nMSI, nuclear MSI; mtMSS, mitochondrial stable MSI;
MSI-S, stable MSI; MSI-L, low-level MSI; MSI-H, high-level MSI.
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products are subsequently transported into the mitochondria.
This indicates that there might be a common cause for the
onset of mtMSI and nMSI. In the present study,
mitochondrial and nuclear instability were examined in 100
GCs. The prevalence of mtMSI and nMSI-H in gastric
cancer varies among different studies, and the relationship
between the occurrence of these alterations remains
controversial [8, 9, 32]. We found that 11% of the gastric
cancer patients had alterations in the D310 poly-C tract in the
D-loop; 13% of the cases showed MSI-H, 5% MSI-L and
82% MSS. These data are in concordance with previous studies
[8, 9]. The mtMSI was significantly associated with nMSI, in
fact, nine of 11 cases positive for mtMSI showed MSI-H. In
several studies, the MSI-H, mtMSI and RUNX3 promoter
methylation in GC have been associated with several
clinicopathological variables, although several reports come to
different conclusions [30–34]. In the present study, no
association was found with any of the clinicopathologic
variables; mitochondrial instability only proved to be
associated with the TNM staging. Up to now, no study had ever
examined the relationship between RUNX3 promoter
methylation, nuclear and mitochondrial MSI in GC. Our data
highlight a significant association between these events in
gastric cancer, suggesting that RUNX3 is an important target of
methylation in the evolution of mtMSI and nMSI-H GC.
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